OTLK

2.0797

5.57% 0.1097

Vorhandelsmarkt: 2.06 -0.0197 -0.95%

Outlook Therapeutics Inc (OTLK)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.97

Offen:

$1.97

24-Stunden-Volumen:

2.21M

Relative Volume:

0.70

Marktkapitalisierung:

$92.38M

Einnahmen:

Nettoeinkommen (Verlust:

$-51.50M

KGV:

-0.5199

EPS:

-4

Netto-Cashflow:

$-47.10M

1W Leistung:

+23.79%

1M Leistung:

+71.88%

6M Leistung:

+8.88%

1J Leistung:

+25.28%

1-Tages-Spanne:

$1.93

$2.10

1-Wochen-Bereich:

$1.7095

$2.10

52-Wochen-Spanne:

$0.79

$3.39

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Firmenname

Outlook Therapeutics Inc

Sektor

Healthcare (1131)

Branche

Biotechnology (632)

Telefon

(609) 619-3990

Adresse

111 S. WOOD AVENUE, ISELIN, NJ

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-08-14

Neueste SEC-Einreichungen

OTLK's Discussions on Twitter

Vergleichen Sie OTLK mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OTLK Outlook Therapeutics Inc	2.0797	87.51M	0	-51.50M	-47.10M	-4.00
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-29	Herabstufung	H.C. Wainwright	Buy → Neutral
2025-08-28	Herabstufung	Guggenheim	Buy → Neutral
2024-12-02	Herabstufung	Chardan Capital Markets	Buy → Neutral
2024-03-27	Hochstufung	BTIG Research	Neutral → Buy
2024-02-15	Hochstufung	Chardan Capital Markets	Neutral → Buy
2024-01-25	Hochstufung	Guggenheim	Neutral → Buy
2023-12-27	Hochstufung	CapitalOne	Equal Weight → Overweight
2023-08-31	Herabstufung	Chardan Capital Markets	Buy → Neutral
2023-08-31	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-08-30	Herabstufung	BTIG Research	Buy → Neutral
2023-08-30	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2023-08-30	Herabstufung	CapitalOne	Overweight → Equal Weight
2023-08-30	Herabstufung	Guggenheim	Buy → Neutral
2023-07-13	Eingeleitet	CapitalOne	Overweight
2023-04-03	Eingeleitet	Guggenheim	Buy
2023-02-06	Eingeleitet	Cantor Fitzgerald	Overweight
2022-10-31	Eingeleitet	BTIG Research	Buy
2022-09-13	Eingeleitet	Chardan Capital Markets	Buy
2019-09-11	Eingeleitet	Ladenburg Thalmann	Buy
2019-05-16	Eingeleitet	Oppenheimer	Outperform
2019-04-22	Eingeleitet	Ascendiant Capital Markets	Buy

Alle ansehen

Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten

02:07 AM

Will Outlook Therapeutics Inc. (41O) stock enhance shareholder valuePortfolio Return Report & Smart Money Movement Alerts - Newser

02:07 AM

How Outlook Therapeutics Inc. stock benefits from tech adoptionEarnings Risk Summary & Real-Time Chart Breakout Alerts - Newser

02:07 AM

01:17 AM

How Outlook Therapeutics Inc. (41ON) stock performs during market turbulenceWatch List & Safe Entry Point Identification - Newser

01:17 AM

Dec 04, 2025

How Outlook Therapeutics Inc. (41O) stock moves in volatile trading sessionsJuly 2025 Reactions & Free Daily Entry Point Trade Alerts - Newser

Dec 04, 2025

What hedge fund moves indicate for Outlook Therapeutics Inc. (41O) stockJuly 2025 Rallies & Free Safe Entry Trade Signal Reports - Newser

Dec 04, 2025

How Outlook Therapeutics Inc. (41O) stock expands through international marketsOil Prices & Low Drawdown Investment Strategies - Newser

Dec 04, 2025

How Outlook Therapeutics Inc. (41O) stock trades under stagflationSwing Trade & Accurate Intraday Trading Signals - Newser

Dec 04, 2025

Will Outlook Therapeutics Inc. (41ON) stock maintain strong growthJuly 2025 Chart Watch & Free Technical Pattern Based Buy Signals - Newser

Dec 04, 2025

Can Outlook Therapeutics Inc. stock outperform in 2025 bull marketPortfolio Value Summary & Daily Stock Trend Watchlist - Newser

Dec 04, 2025

Why institutional investors increase stakes in Outlook Therapeutics Inc. (41ON) stockWeekly Volume Report & Real-Time Market Sentiment Reports - Newser

Dec 04, 2025

Dec 03, 2025

Can Outlook Therapeutics Inc. (41O) stock stage a strong rebound this quarterEarnings Risk Summary & Weekly High Conviction Trade Ideas - Newser

Dec 03, 2025

Will Outlook Therapeutics Inc. (41ON) stock enhance shareholder valueGap Up & Weekly Momentum Stock Picks - Newser

Dec 03, 2025

How Outlook Therapeutics Inc. (41O) stock benefits from digital adoptionMarket Weekly Review & Safe Entry Momentum Tips - Newser

Dec 03, 2025

Dec 02, 2025

Is Outlook Therapeutics Inc. (41O) stock a defensive play amid uncertaintyEarnings Overview Summary & Stock Portfolio Risk Management - Newser

Dec 02, 2025

Will Outlook Therapeutics Inc. (41O) stock beat value stocksMarket Trend Review & Low Risk Profit Maximizing Plans - Newser

Dec 02, 2025

Is Outlook Therapeutics Inc. (41ON) stock worth buying before Fed actionExit Point & Weekly Watchlist of Top Performers - Newser

Dec 02, 2025

Is Outlook Therapeutics Inc. (41ON) stock a top pick for value investors - Newser

Dec 02, 2025

How strong is Outlook Therapeutics Inc. (41ON) stock earnings growthPortfolio Value Summary & High Conviction Investment Ideas - Newser

Dec 02, 2025

Outlook Therapeutics (OTLK) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025

Dec 01, 2025

Stock Report: What makes Outlook Therapeutics Inc stock attractive to growth fundsMarket Sentiment Report & Technical Entry and Exit Alerts - BỘ NỘI VỤ

Dec 01, 2025